Elexacaftor/Tezacaftor/Ivacaftor Increases Vitamin A and D in Cystic Fibrosis
Researchers assessed the effect of elexacaftor/tezacaftor/ivacaftor (ETI) on vitamin A, D, E, and K levels in people with cystic fibrosis.
Diagnosis & Disease Information
Orkambi Indication Expanded to Include More Children With Cystic Fibrosis
The safety profile of Orkambi was found to be similar in patients aged 1 to less than 2 years compared with those 2 years of age and older.
How Do Patients Decide on Treatment for Cystic Fibrosis Exacerbations?
When choosing among alternative treatments for cystic fibrosis exacerbations, what are patients’ and caregivers’ greatest health concerns?
Trikafta Approval Expanded to Include Younger Cystic Fibrosis Patients
The approval was based on data from a phase 3 study that evaluated Trikafta in 66 children 6 to 11 years of age with CF who were either homozygous for the F508del mutation or heterozygous for the F508del mutation and 1 minimal function mutation.
Assessing the Risk of SARS-CoV-2 Infection in Patients With Cystic Fibrosis
While a subset of people with cystic fibrosis may experience a more severe clinical course of COVID-19, they are not at an increased risk of contracting SARS-CoV-2 compared with the general population.
- Loading...
Loading...
Next post in News
Loading... 
Loading...